Loading clinical trials...
Loading clinical trials...
Satisfaction, Adherence, Effectiveness, and Safety of Clindamycin Phosphate, Adapalene, and Benzoyl Peroxide Treatment in Patients With Acne Vulgaris: A Canadian Prospective Phase IV Study (CHARM)
The goal of this observational study is to learn about the effects of a treatment that contains clindamycin phosphate, adapalene, and benzoyl peroxide in people with acne. The main questions the study aims to answer are: * How satisfied are people with this treatment? * How well do people follow the treatment plan? * How effective and safe is the treatment? * How does the treatment affect quality of life? * How do people use other skin care products, such as cleansers, moisturizers, and sunscreen, while using this treatment? About 200 people aged 12 and older with acne across Canada will use the treatment as part of their regular care and answer questions about their experience over 20 weeks.
This is a Phase IV, observational, prospective, multi-center study designed to evaluate treatment satisfaction, adherence, effectiveness, safety, tolerability, quality of life, and skin care product utilization patterns in patients with acne vulgaris who are treated with a topical gel containing clindamycin phosphate 1.2%, adapalene 0.15%, and benzoyl peroxide 3.1% in routine clinical practice across Canada. Approximately 200 patients aged 12 years and older will be enrolled at about 20 dermatology centers.
Age
12 - No limit years
Sex
ALL
Healthy Volunteers
No
CHARM Site 001
Edmonton, Alberta, Canada
CHARM Site 017
Surrey, British Columbia, Canada
CHARM Site 012
Vancouver, British Columbia, Canada
CHARM Site 003
Winnipeg, Manitoba, Canada
CHARM Site 021
Hamilton, Ontario, Canada
CHARM Site 010
Markham, Ontario, Canada
CHARM Site 013
Newmarket, Ontario, Canada
CHARM Site 022
North York, Ontario, Canada
CHARM Site 015
Ottawa, Ontario, Canada
CHARM Site 011
Richmond Hill, Ontario, Canada
Start Date
October 2, 2025
Primary Completion Date
August 1, 2026
Completion Date
August 1, 2026
Last Updated
January 21, 2026
200
ESTIMATED participants
clindamycin phosphate, adapalene and benzoyl peroxide
DRUG
Lead Sponsor
Bausch Health Americas, Inc.
NCT05891795
NCT06501560
NCT03883269
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions